Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 5/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 7/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.47 |
| ▸ | PRKDC | P78527 | 1/20 | 0.47 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16091811 | 0.89 | PIK3CG (0.62) | PIK3CGKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL12387651 | 0.89 | PIK3CG (0.60) | PIK3CGKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL3625455 | 0.89 | RXFP1 (0.72) | PIK3CGRXFP1KDM4ENPSR1MEN1 | |
| SCHEMBL12364316 | 0.88 | PIK3CG (0.66) | PIK3CGKDM4ENPSR1MEN1KMT2A | |
| SCHEMBL189222 | 0.88 | PIK3CG (0.61) | PIK3CGKDM4ENPSR1MEN1KMT2A | |
| SCHEMBL189918 | 0.88 | PIK3CG (0.61) | PIK3CGKDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL189812 | 0.85 | PIK3CG (0.63) | PIK3CGKDM4ENPSR1MEN1KMT2A | |
| SCHEMBL189686 | 0.84 | PIK3CG (0.61) | PIK3CGKDM4EMEN1KMT2APOLB | |
| SCHEMBL189772 | 0.84 | PIK3CG (0.61) | PIK3CGKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL189356 | 0.84 | PIK3CG (0.61) | PIK3CGKDM4ENPSR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118076-B1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO SA (CH) | 2019-09-04 | — | — | EP | disclosed |
| EP-2118076-B1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO SA (CH) | 2019-09-04 | — | — | EP | disclosed |
| US-10328069-B2 | Phosphatidylinositol 3-kinase inhibitors for the treatment of lymphoproliferative malignancies | EXELIXIS, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-10328069-B2 | Phosphatidylinositol 3-kinase inhibitors for the treatment of lymphoproliferative malignancies | EXELIXIS, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| EP-2773353-B1 | N-(3-{[(3-{[2-CHLORO-5-(METHOXY)PHENYL]AMINO}QUINOXALIN-2-YL)AMINO]SULFONYL}PHENYL)-2-METHYLALANINAMIDE AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR FOR THE TREATMENT OF LYMPHOPROLIFERATIVE MALIGNANCIES | EXELIXIS INC (US) | 2018-09-05 | — | — | EP | disclosed |
| US-20170296529-A1 | Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Lymphoproliferative Malignancies | EXELIXIS, INC. | 2017-10-19 | — | — | US | disclosed |
| US-20170296529-A1 | Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Lymphoproliferative Malignancies | EXELIXIS, INC. | 2017-10-19 | — | — | US | disclosed |
| US-20170296529-A1 | Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Lymphoproliferative Malignancies | EXELIXIS, INC. | 2017-10-19 | — | — | US | disclosed |
| EP-2590654-B1 | COMBINATIONS OF KINASE INHIBITORS FOR THE TREATMENT OF CANCER | EXELIXIS INC (US) | 2016-12-21 | — | — | EP | disclosed |
| US-9011863-B2 | Combinations of kinase inhibitors for the treatment of cancer | EXELIXIS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| EP-2139483-A2 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | Exelixis, Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| CN-101528231-A | Use of PI3K and MEK modulators in the treatment of cancer | EXELIXIS INC (US) | 2009-09-09 | — | — | CN | disclosed |
| EP-2056829-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | Exelixis, Inc. (US) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008127594-A2 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008127594-A2 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| CN-101282948-A | N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors | EXELIXIS INC (US) | 2008-10-08 | — | — | CN | disclosed |
| WO-2008101979-A1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008021389-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021389-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007044729-A2 | N- (3-AMINO-QUINOXALIN-2-YL) -SULFONAMIDE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | EXELIXIS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10328069-B2 | Phosphatidylinositol 3-kinase inhibitors for the treatment of lymphoproliferative malignancies | PIK3C2A, PIK3CA, PIK3C3 | PIK3CG 15/4885RXFP1 4841/4885KDM4E 2623/4885 |
| US-20170296529-A1 | Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Lymphoproliferative Malignancies | PIK3C2A, PIK3CA, PIK3C3 | PIK3CG 15/4885RXFP1 4841/4885KDM4E 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.